[go: up one dir, main page]

PE20040472A1 - Composiciones inhibidoras de la arn polimerasa dependiente de arn del virus de la hepatitis c - Google Patents

Composiciones inhibidoras de la arn polimerasa dependiente de arn del virus de la hepatitis c

Info

Publication number
PE20040472A1
PE20040472A1 PE2003000446A PE2003000446A PE20040472A1 PE 20040472 A1 PE20040472 A1 PE 20040472A1 PE 2003000446 A PE2003000446 A PE 2003000446A PE 2003000446 A PE2003000446 A PE 2003000446A PE 20040472 A1 PE20040472 A1 PE 20040472A1
Authority
PE
Peru
Prior art keywords
rna
hepatitis
virus
cyclopentil
diona
Prior art date
Application number
PE2003000446A
Other languages
English (en)
Inventor
Melwyn A Abreo
Allen John Borchardt
Peter Scott Dragovich
Javier Gonzalez
Ru Zhou
Hui Li
Maria Angelica Linton
Thomas J Prins
John Howard Tatlock
Tanya Michelle Jewell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20040472A1 publication Critical patent/PE20040472A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO QUE PONE EN CONTACTO UNA POLIMERASA VHC CON UN COMPUESTO DE FORMULA I DONDE r ES 0 A 5; R1 ES H, ARILO O HETEROARILO, ENTRE OTROS; R2 ES ISOPROPILO, CICLOPENTILO O CICLOHEXILO, ENTRE OTROS; R3 ES H, HALOGENO, =S, -SH, ENTRE OTROS; R4 ES =O U -OR5; R5 ES UN ALQUILO O H; X-W ES C-CH (CUANDO R4 ES =O), C=C (CUANDO R4 ES OR5) O JUNTO CON R3 Y R4 FORMAN UN GRUPO CICLOALQUILO, HETEROARILO O HETEROCICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS; 6-CICLOPENTIL-6-[2-(4-HIDROXIFENIL)ETIL]DIHIDROPIRAN-2,4-DIONA, 6-CICLOPENTIL-6-(2-NAFTALEN-1-ILETIL)DIHIDROPIRAN-2,4-DIONA Y 6-CICLOPENTIL-6-[2-(4-HIDROXIFENIL)ETIL]DIHIDROPIRAN-2,4-DIONA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ARN POLIMERASA DEPENDIENTE DEL ARN (RdRp) UTILES EN EL TRATAMIENTO DE LA HEPATITIS C
PE2003000446A 2002-05-10 2003-05-07 Composiciones inhibidoras de la arn polimerasa dependiente de arn del virus de la hepatitis c PE20040472A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37943302P 2002-05-10 2002-05-10

Publications (1)

Publication Number Publication Date
PE20040472A1 true PE20040472A1 (es) 2004-08-12

Family

ID=29420530

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000446A PE20040472A1 (es) 2002-05-10 2003-05-07 Composiciones inhibidoras de la arn polimerasa dependiente de arn del virus de la hepatitis c

Country Status (10)

Country Link
US (1) US7115658B2 (es)
AR (1) AR040411A1 (es)
AU (1) AU2003224371A1 (es)
DO (1) DOP2003000641A (es)
GT (1) GT200300105A (es)
PA (1) PA8573401A1 (es)
PE (1) PE20040472A1 (es)
TW (1) TW200306813A (es)
UY (1) UY27798A1 (es)
WO (1) WO2003095441A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
BRPI0507861A (pt) 2004-02-20 2007-07-17 Boehringer Ingelheim Int inibidores de polimerase viral
GEP20094751B (en) * 2004-08-18 2009-08-10 Pfizer Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
MX2007005177A (es) 2004-10-29 2007-06-26 Schering Corp 5-oxo pirazoles y [1,2,4]triazoles sustituidos como agentes antivirales.
CA2619077C (en) 2005-08-24 2011-09-13 Pfizer Inc. Methods for the preparation of hcv polymerase inhibitors
RU2401268C2 (ru) * 2005-08-24 2010-10-10 Пфайзер Инк. КРИСТАЛЛИЧЕСКАЯ ФОРМА (R)-6-ЦИКЛОПЕНТИЛ-6-(2-(2,6-ДИЭТИЛПИРИДИН-4-ИЛ)ЭТИЛ)-3-((5,7-ДИМЕТИЛ-[1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-2-ИЛ)МЕТИЛ)-4-ГИДРОКСИ-5,6-ДИГИДРОПИРАН-2-ОНА, ЕЕ ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЕЕ
DK2320905T3 (en) 2008-08-11 2017-09-18 Glaxosmithkline Llc Corp Service Company New adenine derivatives
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010018131A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
PL2534149T3 (pl) 2010-02-10 2015-03-31 Glaxosmithkline Llc Maleinian 6-amino-2-{[(1s)-1-metylobutylo]oksy}-9-[5-(1-piperydynylo)pentylo]-7,9-dihydro-8h-puryn-8-onu
EP3107915B1 (en) 2014-02-20 2017-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
CA2967248A1 (en) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
HK1250032A1 (zh) 2015-12-03 2018-11-23 Glaxosmithkline Intellectual Property Development Limited 作为sting调节剂的环状嘌呤二核苷酸
MX387354B (es) 2016-04-07 2025-03-18 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas.
CN109563081A (zh) 2016-04-07 2019-04-02 葛兰素史克知识产权开发有限公司 可用作蛋白调节剂的杂环酰胺类
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
CN114391015A (zh) 2019-05-16 2022-04-22 斯汀塞拉股份有限公司 苯并[b][1,8]萘啶乙酸衍生物和使用方法
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CA3164751A1 (en) 2019-12-18 2021-06-24 Benjamin Joseph MORROW Compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) * 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
CA1144937A (en) * 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US4326058A (en) * 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) * 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
CA2167537A1 (en) * 1993-07-19 1995-02-02 Tsuneo Ozeki Hepatitis c virus proliferation inhibitor
DE69433705T2 (de) 1993-11-19 2005-03-10 Parke, Davis & Company 5,6-Dihydropyronderivate als Proteaseinhibitoren und Antiviralmittel
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
EP0729463B1 (en) * 1993-11-19 2002-05-22 PARKE DAVIS & COMPANY 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5504104A (en) * 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
US5808062A (en) * 1993-11-19 1998-09-15 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5834506A (en) * 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
WO1999014210A1 (en) * 1997-09-15 1999-03-25 Warner-Lambert Company Process for the preparation of substituted 5,6-dihydro-2h-pyran-2-ones
EP1112269A2 (en) * 1998-09-11 2001-07-04 Warner-Lambert Company Hiv protease inhibitors
CA2358438A1 (en) * 1999-01-07 2000-07-13 David Thomas Dudley Antiviral method using mek inhibitors
US6512006B1 (en) * 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) * 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
CA2480583C (en) * 2002-04-01 2008-07-15 Pfizer Inc. Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase

Also Published As

Publication number Publication date
AU2003224371A1 (en) 2003-11-11
AR040411A1 (es) 2005-04-06
US7115658B2 (en) 2006-10-03
GT200300105A (es) 2004-03-17
US20040023958A1 (en) 2004-02-05
UY27798A1 (es) 2003-12-31
TW200306813A (en) 2003-12-01
PA8573401A1 (es) 2003-12-10
DOP2003000641A (es) 2003-11-15
WO2003095441A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
PE20040472A1 (es) Composiciones inhibidoras de la arn polimerasa dependiente de arn del virus de la hepatitis c
PE20060381A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
PE20060677A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones que los contienen
DK1654261T3 (da) Hepatitis C-inhibitorforbindelser
ECSP066780A (es) Inhibidores de polimerasa viral
MXPA02012906A (es) Inhibidores de polimerasa viral.
PE20051150A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
EA200700038A1 (ru) Ингибиторы вирусных полимераз
NO20062339L (no) Hepatitt C virus-inhibitoerer
EA200400986A1 (ru) Гетероциклические трипептиды в качестве ингибиторов вируса гепатита c
CO5640140A2 (es) Inhibidores de actividad de akt
AR069740A1 (es) Compuestos nucleosidos antivirales
PE20040940A1 (es) Derivados de 3-cicloalquil-indol como inhibidores de la polimerasa del virus de hepatitis c
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
AR045938A1 (es) Peptidos macrociclicos activos contra el virus de la hepatitis c
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
EA201070782A1 (ru) Производные оксадиазола, активные в отношении сфингозин-1-фосфата(sip)
PE20040531A1 (es) Derivados de isoindolona, proceso de preparacion, compuestos intermedios de este proceso y composiciones farmaceuticas que los contienen
PE20220252A1 (es) Compuestos de pirrol
YU12992A (sh) 2-amino-1,2,3,4,-tetrahidronaftaleni supstituisani u prstenu
PE20021018A1 (es) DERIVADOS DE ß - CARBOLINA
DE602004031435D1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
EP1357124A4 (en) HETEROCYCLIC COMPOUNDS AND COMPOSITIONS IMPROVING CEREBRAL FUNCTIONS CONTAINING THESE AS ACTIVE INGREDIENTS
CO5251424A1 (es) Oxazinquinolonas utiles en el tratamiento de infecciones virales

Legal Events

Date Code Title Description
FA Abandonment or withdrawal